Lotronex alosetron selective 5-HT3 receptor antagonist regulatory update

The FDA said that as of Oct. 20, it has received 49 post-marketing reports of ischemic colitis and 21 reports of serious constipation complications, including 5 deaths, among patients taking GLXO's Lo...